EXETER, N.H.--(BUSINESS WIRE)--Apr 10, 2007 - Bentley
Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical
company, today announced that its abstract entitled "Interim
Results of a Randomized, Single-Dose, 4-Way Crossover,
Pharmacokinetic Study of Intranasal Insulin Spray (Nasulin(TM)),
Injectable Regular Insulin (Humulin R(R)), Injectable Fast-Acting
Insulin (Humalog(R)), and Saline Nasal Spray in Patients with Type
I Diabetes Mellitus," has been selected for oral presentation at
the American Diabetes Association 67th Scientific Sessions in
Chicago. Dr. Sherwyn L. Schwartz, M.D., of dgd Research, Inc., will
make the presentation as part of the first session on Friday, June
22, 2007.
Another Bentley sponsored study has also been accepted for a
poster presentation in the category Clinical Therapeutics/New
Technology - Insulin Delivery Systems. The poster abstract,
"Intranasulin Insulin Spray (Nasulin(TM)) in Healthy Subjects:
Choice of Nostril," will be displayed Saturday through Monday, June
23-25, 2007, in the General Poster Session in the Exhibit Hall.
Founded in 1979 by Dr. Schwartz, the Diabetes & Glandular
Disease Clinic is the largest private endocrine clinic in the
United States with over 70,000 active patients, eight board
certified endocrinologists, seven NPs/PAs and an ADA recognized
diabetes education program. The research arm, dgd Research
Associates, Inc., has a staff of over 250 employees and has
conducted over 1,500 Phase I through III clinical trials, primarily
in targeted endocrine populations. Currently work is underway on
construction of a new 80,000sq. ft. Phase I unit. For more
information visit www.dgdclinic.com and www.dgdresearch.com.
Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on advanced drug delivery technologies and generic
pharmaceutical products. Bentley's proprietary drug delivery
technologies enhance the absorption of pha
'"/>
Page: 1 2 3 Related medicine technology :1.
Bentley Reports Positive Results with Nasulin Intranasal Insulin
Spray at the American Diabetes Association Meeting2.
Cell Therapeutics, Inc. Management to Discuss Todays Announcement
of Interim Pixantrone Study Results3.
Positive ZIO-201 Interim Phase II Sarcoma Data Presented at
European Society for Medical Oncology4.
Ablynx Announces Interim Results of First Nanobody Phase I Study of
ALX-0081 (ANTI-VWF)5.
Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable
Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical
Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma6.
ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data
Presented at International Myeloma Workshop7.
Accentia Biopharmaceuticals Announces Favorable Interim Blinded
Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial
for Chronic Sinusitis8.
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2
Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat
Recurrent Non-Small Cell Lung Cancer9.
Interim Analysis of Crinone Pregnancy Study to Be Published in
American Society for Reproductive Medicine Journal10.
Avalon Pharmaceuticals Announces Positive Interim Results For
AVN944 Phase I Trial11.
Vical Interim Clinical Results Demonstrate Safety and Tolerability
of Inovio Biomedicals Electroporation DNA Delivery Technology